Glucose Viaflo Baxter

Glucose Viaflo Baxter is an intravenous solution containing glucose as the sole active ingredient, supplied in a sterile liquid form for parenteral administration. It is manufactured for the European market and is used as an energy source in clinical settings where oral intake is not possible. The product provides a readily available carbohydrate to support blood glucose levels and fluid balance during medical treatment in hospitals.

Glucose Viaflo Baxter is indicated for several clinical situations where rapid carbohydrate supplementation or fluid replacement is required.

- Management of hypoglycemia in patients unable to take oral glucose. - Component of parenteral nutrition regimens for patients receiving total parenteral nutrition. - Fluid and electrolyte replacement in perioperative or trauma care. - Support during dialysis or continuous renal replacement therapy. - Provision of caloric intake in critically ill patients when enteral feeding is contraindicated. - Use as a diluent for compatible intravenous medications requiring a glucose-containing carrier.

Glucose Viaflo Baxter may be associated with a range of adverse reactions, most of which are related to its osmolarity and glucose content.

Common: - Transient hyperglycemia, especially in patients with impaired insulin response. - Local irritation or phlebitis at the infusion site. - Electrolyte shifts such as mild hyponatremia or hypokalemia due to dilutional effects. - Mild nausea or vomiting related to rapid infusion rates.

Serious: - Severe hyperglycemia leading to osmotic diuresis or ketoacidosis in susceptible individuals. - Hypersensitivity reactions including rash, urticaria, or anaphylaxis. - Fluid overload resulting in pulmonary edema, particularly in patients with cardiac or renal impairment. - Hyperosmolar state causing neurologic symptoms such as confusion or seizures.

When administering Glucose Viaflo Baxter, clinicians should observe specific precautions to minimize risks and ensure appropriate therapeutic outcomes.

- Assess baseline blood glucose and adjust infusion rate to avoid excessive hyperglycemia. - Verify patient’s fluid status and cardiac function to prevent volume overload. - Use aseptic technique and inspect the solution for particulate matter before infusion. - Monitor electrolytes, particularly sodium and potassium, during prolonged therapy. - Consider contraindications in patients with known glucose intolerance, uncontrolled diabetes, or severe renal impairment. - Adjust dosage in pediatric or geriatric populations based on weight and metabolic needs.

Glucose Viaflo Baxter can interact with other intravenous agents or systemic medications; awareness of these interactions helps maintain safety.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring, which may precipitate severe hypoglycemia. - Simultaneous infusion of hypertonic saline solutions that could exacerbate hyperosmolar states. - Mixing with calcium‑containing solutions may cause precipitation and should be avoided.

Use with caution: - Concurrent use of diuretics that may alter electrolyte balance, requiring closer monitoring. - Administration alongside potassium‑containing solutions, as glucose infusion can shift potassium intracellularly. - Use with catecholamine vasopressors, since rapid glucose changes may affect hemodynamic responses. - When combined with parenteral lipid emulsions, monitor triglyceride levels to prevent hypertriglyceridemia.